Printer Friendly

Fervent Pharmaceuticals to Initiate Clinical Trial of New Menopause Therapy.

M2 PHARMA-January 2, 2018-Fervent Pharmaceuticals to Initiate Clinical Trial of New Menopause Therapy

(C)2018 M2 COMMUNICATIONS

- Greenville, North Carolina-based drug development company Fervent Pharmaceuticals has successfully submitted an investigational new drug application to the US Food and Drug Administration for FP-101, its proprietary lead drug candidate for treating menopause symptoms, especially hot flashes, the company said.

A Phase 2a clinical trial will now begin to assess the therapeutic potential of FP-101 in post-menopausal women. The trial will enroll 110 women at a dozen study sites in Illinois, North Carolina, South Carolina, and Tennessee.

FP-101 is an orally dosed, non-hormonal, non-herbal, non-antidepressant formulation of a compound that has known mechanisms of action, is already FDA approved for another undisclosed indication, and has a long history of safe use.

Fervent has received assistance from the North Carolina Biotechnology Center and its Eastern Regional Office, headed by Mark Phillips, vice president of statewide operations and executive director of the office.

The company is working with the University of Iowa Pharmaceuticals on drug formulation, and with IQVIA (formerly QuintilesIMS) of Durham and PMG Research of Winston-Salem for clinical trial design and execution.

Fervent, founded in 2011, is focused on developing therapies targeting unmet medical needs in women's health.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:1U5NC
Date:Jan 2, 2018
Words:216
Previous Article:FDA Clears Ignyta IND for Novel Immunomodulatory Agent and TAM Inhibitor.
Next Article:Healthcare EDI Market Expected to Reach USD 5.9bn by 2025.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters